1. Home
  2. TAC vs BLLN Comparison

TAC vs BLLN Comparison

Compare TAC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAlta Corporation

TAC

TransAlta Corporation

HOLD

Current Price

$13.48

Market Cap

3.5B

Sector

Utilities

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$80.08

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TAC
BLLN
Founded
1909
2016
Country
Canada
United States
Employees
1350
713
Industry
Electric Utilities: Central
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TAC
BLLN
Price
$13.48
$80.08
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$23.67
$126.71
AVG Volume (30 Days)
1.1M
315.0K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
1.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$45.96
Revenue Next Year
$1.97
$30.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.34
$61.96
52 Week High
$17.88
$138.70

Technical Indicators

Market Signals
Indicator
TAC
BLLN
Relative Strength Index (RSI) 53.55 51.64
Support Level $13.41 $80.39
Resistance Level $14.00 $83.20
Average True Range (ATR) 0.39 6.78
MACD 0.04 0.23
Stochastic Oscillator 52.29 50.20

Price Performance

Historical Comparison
TAC
BLLN

About TAC TransAlta Corporation

TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: